Superior vena cava syndrome epidemiology and demographics
|
Superior Vena Cava Syndrome Microchapters |
|
Differentiating Superior Vena Cava Syndrome from Other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Superior vena cava syndrome epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Superior vena cava syndrome epidemiology and demographics |
|
FDA on Superior vena cava syndrome epidemiology and demographics |
|
CDC on Superior vena cava syndrome epidemiology and demographics |
|
Superior vena cava syndrome epidemiology and demographics in the news |
|
Blogs on Superior vena cava syndrome epidemiology and demographics |
|
Directions to Hospitals Treating Superior vena cava syndrome |
|
Risk calculators and risk factors for Superior vena cava syndrome epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Overview
Superior vena cava syndrome is a common oncologic emergency. The incidence rate in the United States of SVCS is approximately 15,000 individuals each year. The incidence of superior vena cava syndrome increases with age; SVCS affects adults with more frequency, and it is less common in children and young adults. The median age of diagnosis is between 40-60 years. Males are slightly more affected than women.[1]
Epidemiology and demographics
Prevalence
- The prevalence of SVCS remains unknown.
Incidence
- In the United States, the incidence of superior vena cava syndrome is 15,000 each year.[1]
Gender
- Males are more commonly affected than females because of the high incidence of lung cancer among patients with SVCS.[2]
Race
- The prevalence of SVCS does not vary by race. However, depending on the type of cancer a racial predilection may be possible.